Graham Cooper barrels in as Geron CFO
This article was originally published in Clinica
Executive Summary
Geron Corporation has appointed Graham Cooper executive vice-president of finance and business development and chief financial officer. From 2006 to 2011, Mr Cooper served as senior vice-president, CFO and treasurer of Orexigen Therapeutics, where he was instrumental in growing the company from a venture-backed start-up into a sizeable public company. Geron recently put its stem cell assets up for sale, and dropped its clinical programme for GRNOPC1, a stem cell therapy for acute spinal cord injury that had been in a Phase I trial (www.clinica.co.uk, 15 November 2011). The company now plans to concentrate on its drugs imetelstat and GRN1005, which are in Phase II studies.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.